Back to top
more

CytomX Therapeutics, Inc. (CTMX)

(Real Time Quote from BATS)

$11.38 USD

11.38
30,677

-0.24 (-2.07%)

Updated Jul 22, 2019 11:00 AM ET

Add to portfolio

1-Strong Buy 1        

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.80%
17.93%
9.58%
5.18%
2.03%
10.63%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | F Growth | B Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Balance Sheet

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for CTMX

 

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

Fiscal Year End for CytomX Therapeutics, Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Assets          
Cash & Equivalents 436 374 182 187 65
Receivables 0 10 2 1 2
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 9 4 4 2 0
Total Current Assets 445 389 188 190 67
Net Property & Equipment 7 4 4 3 3
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 2 3 3 3 3
Deposits & Other Assets 2 2 4 1 0
Total Assets 457 398 199 197 73
Liabilities & Shareholders Equity 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Notes Payable 0 0 0 0 0
Accounts Payable 5 4 7 5 2
Current Portion Long-Term Debt 0 0 0 0 1
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 27 16 9 5 2
Income Taxes Payable 13 0 0 0 0
Other Current Liabilities 53 41 20 6 6
Total Current Liabilities 98 61 36 16 11
Mortgages 0 0 0 0 0
Deferred Taxes/Income 225 265 84 55 61
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 2
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 3 2 1 0 0
Minority Interest (Liabilities) 0 0 0 0 1
Total Liabilities 326 328 121 71 75
Shareholders Equity 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Preferred Stock 0 0 0 0 77
Common Stock (Par) 0 0 0 0 0
Capital Surplus 446 289 255 244 0
Retained Earnings -315 -219 -176 -117 -78
Other Equity 0 0 0 -0 -0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 131 70 78 126 -2
Total Liabilities & Shareholder's Equity 457 398 199 197 73
Total Common Equity 131 70 78 126 -79
Shares Outstanding 45.00 38.40 36.40 36.00 NA
Book Value Per Share 2.91 1.82 2.16 3.50 0.00

Fiscal Year End for CytomX Therapeutics, Inc. falls in the month of December.

All items in Millions except Per Share data.

6/30/2019 3/31/2019 12/31/2018 9/30/2018 6/30/2018
Assets          
Cash & Equivalents NA 397 436 465 335
Receivables NA 0 0 0 25
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 8 9 8 6
Total Current Assets NA 405 445 473 367
Net Property & Equipment NA 7 7 5 6
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 2 2 2 2
Deposits & Other Assets NA 30 2 2 2
Total Assets NA 445 457 483 377
Liabilities & Shareholders Equity 6/30/2019 3/31/2019 12/31/2018 9/30/2018 6/30/2018
Notes Payable NA 0 0 0 0
Accounts Payable NA 10 5 7 4
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 23 27 21 25
Income Taxes Payable NA 13 13 5 3
Other Current Liabilities NA 51 53 53 52
Total Current Liabilities NA 96 98 86 83
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 198 225 236 250
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 27 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 3 2 2
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 322 326 325 336
Shareholders Equity 6/30/2019 3/31/2019 12/31/2018 9/30/2018 6/30/2018
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 452 446 441 301
Retained Earnings NA -329 -315 -283 -259
Other Equity NA 0 0 -0 -0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 123 131 158 41
Total Liabilities & Shareholder's Equity NA 445 457 483 377
Total Common Equity 0 123 131 158 41
Shares Outstanding 45.30 45.30 45.00 45.00 38.90
Book Value Per Share 0.00 2.71 2.91 3.50 1.06